LQDA Earnings Prediction
The chart below shows how LQDA performed 10 days before and after its earnings report, based on data from the past quarters. Typically, LQDA sees a +0.37% change in stock price 10 days leading up to the earnings, and a -0.69% change 10 days following the report. On the earnings day itself, the stock moves by +2.76%. This data can give you a slight idea of what to expect for the next quarter's release.
LQDA Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
4.45M
20.94%
21.56%
Gross Margin
64.82%
-23.29%
9.49%
Operating Margin
-656.23%
62.08%
-11.71%
Net Margin
-520.57%
21.26%
-31.83%
EPS
-0.30
-25.00%
-18.92%
No Data Available
LQDA Earnings Analysis
Liquidia Corporation Common Stock Corporation (LQDA.O) Earnings Conference Call
Positive
Cash Reserves for Launch: 1. Strong Cash Position: Liquidia ended Q3 2024 with $204.4 million in cash on hand, positioning the company well for the potential launch of YUTREPIA in 2025.
Revenue Surge: 2. Increased Revenue: The company reported revenue of $4.4 million for Q3 2024, a 19% increase from $3.7 million in the same quarter of 2023, primarily driven by higher sales quantities.
ASCENT Study Enrollment Update: 3. Clinical Progress in ASCENT Study: Over one-third of patients have been enrolled in the ASCENT study for YUTREPIA, with preliminary data showing high tolerability and titratability, with patients reaching an average dose of 152.5 micrograms by week 8.
Increased Clinical Site Activity: 4. Expanded Clinical Sites: Liquidia doubled the number of clinical sites for the ASCENT study, with 21 out of 22 sites now active, ensuring robust patient enrollment and data collection.
Strategic Financing Success: 5. Successful Financing: The company executed three simultaneous financing transactions in September 2024, bringing approximately $100 million into the company, enhancing its financial stability for upcoming initiatives.
Negative
Net Loss Increase: 1. Increased Net Loss: Liquidia reported a net loss of $23.2 million for Q3 2024, a significant increase from a net loss of $15.8 million in Q3 2023, reflecting a worsening financial position year-over-year.
R&D Expense Surge: 2. Rising R&D Expenses: Research and development expenses surged to $11.9 million in Q3 2024, up 60% from $7.4 million in the same quarter of 2023, indicating escalating costs associated with clinical programs.
Rising Administrative Expenses: 3. Escalating General and Administrative Costs: General and administrative expenses rose to $20.2 million in Q3 2024, a 91% increase compared to $10.6 million in Q3 2023, driven by higher personnel and legal costs.
Clinical Approval Delays: 4. Delayed Clinical Approval: The final approval of YUTREPIA is contingent on the expiration of TYVASO DPI's clinical exclusivity on May 23, 2025, which has been further complicated by ongoing litigation against the FDA.
Rising Legal Expenses: 5. Increased Legal Expenses: Legal fees related to ongoing litigation concerning YUTREPIA increased by $1.5 million in Q3 2024, contributing to the overall rise in general and administrative expenses.
LQDA FAQs
How does LQDA typically perform around its earnings report dates?
Is Liquidia Corporation (LQDA) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
LQDA Earning Call Sentiment
Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
LQDA.O
-0.27%Positive
The earnings call reveals several negative factors: ongoing litigation risks with the FDA and United Therapeutics, financial strain from increased losses, and operational risks due to rising R&D expenses. Despite some positive financial aspects like a cash influx and revenue growth, the uncertainties surrounding YUTREPIA's approval and competitive pressures overshadow these. The Q&A further highlights management's inability to provide clear guidance on critical issues, exacerbating investor concerns. Thus, the stock price is likely to experience a negative reaction in the short term.
